Showing results (611-620 of 5,044) with videos related to

Sort By:
Pageof 505
Multiple Sclerosis and Related Disorders|April 22, 2023
Validation of the Spanish version of DYsphagia in MUltiple Sclerosis questionnaire (DYMUS)Marta Renom, Ingrid Galán, Xavier Vidal, et al.
Multiple Sclerosis and Related Disorders|April 26, 2023
The consequences of switching from Gilenya® to generics for fingolimodLeslie Menendez, Michael Osherov, Zeev Nitsan, et al.
Multiple Sclerosis and Related Disorders|April 14, 2023
Multiple sclerosis and anxiety: Is there an untapped opportunity for exercise?Petra Šilić, Robert W Motl, Jennifer Duffecy
Multiple Sclerosis and Related Disorders|April 17, 2023
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosisE M E Coerver, A Bourass, M H J Wessels, et al.
Multiple Sclerosis and Related Disorders|April 17, 2023
Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohortHaris Majid Rajput, Muhammad Hassan, Mazhar Badshah
Multiple Sclerosis and Related Disorders|May 6, 2023
Clinical characteristics and prognosis of optic neuritis in Taiwan - a hospital-based cohort studyChao-Wen Lin, Wei-Tse Chen, Yen-Heng Lin, et al.
Multiple Sclerosis and Related Disorders|May 8, 2023
Characterizing cannabis use in a sample of adults with multiple sclerosis and chronic pain: An observational studyKara Link, Lindsey M Knowles, Kevin N Alschuler, et al.
Multiple Sclerosis and Related Disorders|May 8, 2023
A comparative study of visual outcome in patients with optic neuritis treated with five or seven days of intravenous corticosteroid treatmentGuilherme Diogo Silva, Sara Terrim, Fernando Cavalcantide Sá E Benevides Falcão, et al.
Multiple Sclerosis and Related Disorders|April 5, 2021
A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysisMengJiao Sun, Ning Liu, QinFang Xie, et al.
Multiple Sclerosis and Related Disorders|August 25, 2020
COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVIDCelsi Fiorella, Galleguillos Lorna
Pageof 505